Full Year 2023 Investor Presentation
98
Investor presentation
Full year 2023
ZEUS trial with ziltivekimab aims to validate the link between
inflammation and major adverse cardiovascular events
R
1:1
Phase 3 CVOT trial ZEUS with ziltivekimab
Investigate CV benefit in 6,200 patients
ziltivekimab 15 mg sc once-monthly + SoC
Placebo sc once-monthly + SoC
Treatment period
(event driven)
3 months
follow-up
Novo NordiskⓇ
Objective
•
•
To investigate the cardiovascular benefit of ziltivekimab in the
treatment of patients with established ASCVD, CKD and
systemic inflammation
Primary endpoints
Time to the first occurrence of 3-point MACE (CV death, non-
fatal MI or non-fatal stroke)
Secondary confirmatory endpoints
Time to first occurrence of expanded MACE¹
•
Number of hospitalisations for HF or urgent HF visit
•
Time to occurrence of all-cause mortality
.
Time to first occurrence of a composite CKD endpoint
1 MACE includes CV death, non-fatal MI or non-fatal stroke, Expanded MACE includes: (CV death, non-fatal MI, non-fatal stroke or hospitalisation for unstable angina pectoris requiring urgent coronary revascularisation)
hsCRP: High-sensitivity C-reactive protein; CVOT: Cardiovascular outcome trial; CV: Cardiovascular; sc: Subcutaneous; SoC: Standard of care; HF: Heart failure; CKD: Chronic kidney disease
Source: Ridker PM, et al., IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial, 17 May 2021View entire presentation